If such a class were to be recognized, it would imply a group of chemical compounds specifically designed to modulate the activity of the biological entity termed 'pelota'. Assuming 'pelota' refers to a protein or biochemical pathway, activators of this class would interact with the 'pelota' entity to enhance its biological function. This could be through direct binding to the protein, which may stabilize it in an active conformation, or by facilitating its interaction with other proteins or substrates. The nature of these activators would be determined by the structural requirements of the 'pelota' binding sites, leading to a diverse array of molecular structures, possibly encompassing small organic compounds, peptides, or other biologically active molecules, each with specific affinities and selectivities towards their target.
The identification and development of 'pelota Activators' would involve a combination of computational chemistry and experimental biology. Initially, a detailed understanding of the 'pelota' structure and function would be required, which could be gleaned from X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy data. With this information, virtual screening processes could be employed to identify potential activator compounds, which would then be synthesized and assessed for their ability to enhance 'pelota' activity. Biochemical assays would be crucial for this assessment, testing the effects of these compounds on the activity of 'pelota' in vitro. Such assays would likely include activity measurements in the presence of substrate molecules or binding studies to determine the affinity and kinetics of interaction between the 'pelota' protein and the activators. The results of these experiments would inform further optimization of the compounds, potentially leading to the development of a diverse chemical class of 'pelota Activators'. However, it is important to note that this concept is speculative and is not based on current scientific consensus or literature.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | ¥451.00 ¥925.00 ¥2888.00 | 127 | |
抑制真核蛋白质合成,从而导致上调核糖体循环因子(如 PELO)的应激反应。 | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | ¥451.00 ¥2369.00 ¥9206.00 ¥733.00 | 394 | |
在蛋白质合成过程中导致链过早终止,可能会增加对核糖体循环机制的需求。 | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | ¥1094.00 ¥2866.00 | 36 | |
通过阻断肽键的形成来抑制蛋白质的合成,从而可能引发细胞反应,上调 PELO。 | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | ¥598.00 | 10 | |
与细菌核糖体结合并抑制蛋白质合成,这可能会增强核糖体相关蛋白质的表达。 | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | ¥824.00 ¥2685.00 ¥8089.00 ¥28453.00 ¥241660.00 | 53 | |
与 DNA 相互结合并阻止 RNA 合成,这可能会间接影响蛋白质合成途径,从而影响 PELO 的表达。 | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | ¥3971.00 ¥6386.00 ¥15016.00 ¥27675.00 | ||
通过阻断转运抑制蛋白质合成,可能导致核糖体循环蛋白表达增加。 | ||||||
Tetracycline | 60-54-8 | sc-205858 sc-205858A sc-205858B sc-205858C sc-205858D | 10 g 25 g 100 g 500 g 1 kg | ¥699.00 ¥1038.00 ¥2990.00 ¥4614.00 ¥7017.00 | 6 | |
抑制细菌蛋白质合成,并可能间接导致应激反应下核糖体救援因子的上调。 | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | ¥2933.00 ¥11609.00 | 26 | |
抑制 RNA 聚合酶 II 并影响 mRNA 合成,这可能间接导致核糖体循环蛋白水平的变化。 |